Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) ...

Lenacapavir is in Phase 3 development for HIV prevention. FDA-Approved Products for HIV Treatment: Lenacapavir (brand name: Sunlenca), in combination with ...

HIV-1 Infection. Indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant infection whose current ...

INDICATION. SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ...

Lenacapavir (brand name: Sunlenca) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in ...

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

17 авг. 2022 г. · Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear ...

Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) ...

31 янв. 2024 г. · Lenacapavir injection is used together with other medicines to treat human immunodeficiency virus (HIV) infection in patients who have previously received ...

Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen.